Technical Analysis for FLGT - Fulgent Genetics, Inc.

Grade Last Price % Change Price Change
F 17.14 -0.81% -0.14
FLGT closed up 1.65 percent on Wednesday, November 20, 2024, on 1.35 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -0.81%
NR7 Range Contraction -0.81%
Wide Bands Range Expansion -0.81%
Oversold Stochastic Weakness -0.81%
New 52 Week Low Weakness 0.82%
Outside Day Range Expansion 0.82%
Wide Bands Range Expansion 0.82%
Oversold Stochastic Weakness 0.82%
New 52 Week Closing Low Bearish 2.57%
NR7 Range Contraction 2.57%

   Recent Intraday Alerts

Alert Time
1.5x Volume Pace about 3 hours ago
Down 1% about 3 hours ago
Rose Above Previous Day's High about 3 hours ago
Up 2% about 3 hours ago
Up 1% about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fulgent Genetics, Inc. Description

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Genetics Cardiovascular Disease Medical Genetics Neurological Disorders Medical Test Vascular Disease Molecular Diagnostics Algorithms Applied Genetics Urological Disorders Genetic Testing Qiagen

Is FLGT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.68
52 Week Low 16.56
Average Volume 184,797
200-Day Moving Average 21.65
50-Day Moving Average 20.41
20-Day Moving Average 19.66
10-Day Moving Average 18.52
Average True Range 0.96
RSI (14) 34.21
ADX 35.41
+DI 12.28
-DI 33.97
Chandelier Exit (Long, 3 ATRs) 20.00
Chandelier Exit (Short, 3 ATRs) 19.43
Upper Bollinger Bands 23.25
Lower Bollinger Band 16.08
Percent B (%b) 0.17
BandWidth 36.46
MACD Line -0.92
MACD Signal Line -0.54
MACD Histogram -0.3835
Fundamentals Value
Market Cap 512.06 Million
Num Shares 29.6 Million
EPS -2.10
Price-to-Earnings (P/E) Ratio -8.23
Price-to-Sales 2.68
Price-to-Book 0.60
PEG Ratio 1.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.36
Resistance 3 (R3) 18.32 17.93 18.18
Resistance 2 (R2) 17.93 17.65 17.95 18.12
Resistance 1 (R1) 17.60 17.48 17.77 17.64 18.06
Pivot Point 17.21 17.21 17.29 17.23 17.21
Support 1 (S1) 16.88 16.93 17.05 16.92 16.50
Support 2 (S2) 16.49 16.76 16.51 16.44
Support 3 (S3) 16.16 16.49 16.38
Support 4 (S4) 16.20